Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Acadia pharmaceuticals - Caught on Camera

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo

MarketBeat

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference. Chief Executive Officer Cat

MarketBeat

Women's health is an 'economic blind spot.' Data is the key to reframing the conversation

There’s an urgent need for leadership, innovation, and a redefinition of what it means to design health “for us, by us,” experts said at Fortune’s Most Powerful Women Summit.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

‘We have hope for some breakthroughs’: can we change the way we treat schizophrenia?

Scientists are cautiously optimistic that new approaches to treating the disabling condition may improve the lives of those affected by it

The Guardian - UK

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

Benzinga

Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday.

Benzinga

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Insights

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06 million.

Benzinga

ACADIA Pharmaceuticals: Q1 Earnings Insights

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga

ACADIA Pharmaceuticals's Earnings Outlook

ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that ACADIA Pharmaceuticals will report an earnings per share (EPS) of $-0.60.

Benzinga

What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Expert Ratings For ACADIA Pharmaceuticals

Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Overview

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $130.76 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 198.08%, resulting in a loss of $43.09 million.

Benzinga

Recap: ACADIA Pharmaceuticals Q4 Earnings

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga

Expert Ratings For ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

People

Andrew Miller

106 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.